The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with ...

Abiraterone ... [18,19,101] Enzalutamide Androgen receptor Approved by the FDA for the treatment mCRPC postchemotherapy After chemotherapy, improved median OS 18.4 vs 13.6 months (HR: 0.63 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate ...